Plain-English translation of NCT06689670 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called INT001 for people with liver cancer or tumors that have spread to the liver. The medication is injected directly into the tumor using a needle guided by imaging — similar to how doctors perform other image-guided procedures. The study will see whether this treatment can safely destroy tumors and what side effects patients might experience.
Many people with liver tumors cannot have surgery or transplants because of their health condition. This trial exists to explore whether this new injection-based treatment could be a helpful option for patients who don't qualify for traditional surgery.
You likely qualify if…
You likely don't qualify if…
You would receive the INT001 injection on day 1 of the study, performed as an outpatient procedure. You would then return to the clinic for follow-up visits at days 7, 30, and 90, where you'll have blood tests and imaging scans (like MRI) to see how well the treatment worked and to check for any side effects. The entire study participation lasts about 3 months.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Turkey (Türkiye)
inTumo Therapeutics, Inc.
Enrollment target
~31 participants
Started
October 2024
Primary completion
December 2027
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rahmi Oklu, MD, PhD
Koc University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.